RSV F vaccine (0.5mL injection)

BIOLOGICAL3 trials

Sponsors

Novavax, Northumbria Healthcare NHS Foundation Trust

Conditions

COPDRespiratory Synctial VirusRespiratory Syncytial Virus Infections

Phase 1

A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age

CompletedNCT02296463

NovavaxRespiratory Synctial Virus

Start: 2014-11-30End: 2016-04-30Updated: 2016-04-28

Phase 2

RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.

CompletedNCT02247726

NovavaxRespiratory Syncytial Virus Infections

Start: 2014-09-30End: 2016-07-31Updated: 2022-05-27

Unknown Phase

Structured Review: To Optimise Management and Prevent Harm in COPD

Not yet recruitingNCT07460154

Northumbria Healthcare NHS Foundation TrustCOPD

Start: 2026-03-01End: 2029-03-02Target: 96Updated: 2026-03-10

Related Papers

Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants

The Journal of Infectious Diseases2019-08-0196 citations